Table 3. Resistance profile of osimertinib in real-world practice.
| Group | Patient no. | Before osimertinib | After resistance to osimertinib | Progression-free survival (months) | |||
|---|---|---|---|---|---|---|---|
| Histology | Mutation | Histology | Mutation | First EGFR-TKI |
Osimertinib | ||
| T790M-loss | 1 | Adeno-carcinoma | T790M E19del. |
Adeno-carcinoma | E19del. | 13.0 (Afatinib) |
1.0 |
| 2 | Adeno-carcinoma | T790M E19del. |
Adeno-carcinoma | E19del. | 10.1 (Gefitinib) |
6.1 | |
| 4 | Adeno-carcinoma | T790M E19del. |
Adeno-carcinoma | E19del. | 32.5 (Gefitinib) |
3.2 | |
| 5 | Adeno-carcinoma | T790M L858R |
Adeno-carcinoma | Wild type | 8.2 (Gefitinib) |
4.4 | |
| 6 | Adeno-carcinoma | T790M E19del. |
Small cell carcinoma | E19del. | 12.0 (Gefitinib) |
4.3 | |
| 8 | Adeno-carcinoma | T790M E19del. |
Small cell carcinoma | E19del. | 18.0 (Gefitinib) |
6.5 | |
| 10 | Adeno-carcinoma | T790M L858R |
Adeno-carcinoma | L858R | 14.0 (Gefitinib) |
7.4 | |
| T790M-persistent | 3 | Adeno-carcinoma | T790M L858R |
Adeno-carcinoma | T790M L858R |
6.3 (Gefitinib) |
11.1 |
| 7 | Adeno-carcinoma | T790M E19del. |
Adeno-carcinoma | T790M E19del. |
11.8 (Gefitinib) |
4.7 | |
| 9 | Adeno-carcinoma | T790M E19del. |
Adeno-carcinoma | T790M E19del. C797S |
18.5 (Erlotinib) |
7.7 | |
Abbreviation: EGFR-TKI, epidermal growth factor receptor-tyrosine kinase inhibitor.